Search Results

Filter
  • 1-10 of  184,200 results for ""INFLIXIMAB""

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Report

Adjunctive treatment with infliximab in pediatric immunoglobulin A (IgA) vasculitis: A case report.

  • Authors : Castelli B; Rheumatology Unit, AOU Meyer Children's Hospital, Florence, Italy.; Marrani E

Subjects: IgA Vasculitis*/IgA Vasculitis*/IgA Vasculitis*/drug therapy ; Infliximab*/Infliximab*/Infliximab*/therapeutic use ; Tumor Necrosis Factor Inhibitors*/Tumor Necrosis Factor Inhibitors*/Tumor Necrosis Factor Inhibitors*/therapeutic use

  • Source: Pediatric dermatology [Pediatr Dermatol] 2022 Nov; Vol. 39 (6), pp. 946-949. Date of Electronic Publication: 2022 Jul 02.Publisher: Wiley Country of Publication: United States NLM ID: 8406799 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-1470

Record details

×
Academic Journal

Real-life experience of infliximab biosimilar in pediatric-onset inflammatory bowel disease: data from the Sicilian Network for Inflammatory Bowel Disease.

Subjects: Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/therapeutic use ; Colitis, Ulcerative*/Colitis, Ulcerative*/Colitis, Ulcerative*/diagnosis ; Colitis, Ulcerative*/Colitis, Ulcerative*/Colitis, Ulcerative*/drug therapy

  • Source: European journal of gastroenterology & hepatology [Eur J Gastroenterol Hepatol] 2022 Oct 01; Vol. 34 (10), pp. 1007-1014. Date of Electronic Publication: 2022 Jul 14.Publisher: Lippincott Williams And Wilkins Country of Publication: England NLM ID: 9000874 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
Academic Journal

Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases.

  • Authors : Kantasiripitak W; Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium.; Outtier A

Subjects: Inflammatory Bowel Diseases*/Inflammatory Bowel Diseases*/Inflammatory Bowel Diseases*/drug therapy ; Infliximab*/Infliximab*/Infliximab*/pharmacokinetics ; Infliximab*/Infliximab*/Infliximab*/therapeutic use

  • Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2022 Aug; Vol. 11 (8), pp. 1045-1059. Date of Electronic Publication: 2022 Jun 15.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial.

  • Authors : Brun MK; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Subjects: Antibodies* ; Antirheumatic Agents*/Antirheumatic Agents*/Antirheumatic Agents*/adverse effects ; Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/drug therapy

  • Source: Journal of internal medicine [J Intern Med] 2022 Sep; Vol. 292 (3), pp. 477-491. Date of Electronic Publication: 2022 Apr 26.Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 8904841 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
Academic Journal

Neurotuberculosis with paradoxical reaction treated with infliximab: case report and literature review.

  • Authors : Chia G; Internal Medicine Wellington Regional Hospital, New Zealand.; Bartlett T

Subjects: Infliximab*/Infliximab*/Infliximab*/therapeutic use ; Tuberculosis, Central Nervous System*/Tuberculosis, Central Nervous System*/Tuberculosis, Central Nervous System*/drug therapy; Female

  • Source: The New Zealand medical journal [N Z Med J] 2022 Aug 05; Vol. 135 (1559), pp. 118-121. Date of Electronic Publication: 2022 Aug 05.Publisher: New Zealand Medical Association Country of Publication: New Zealand NLM ID: 0401067 Publication Model: Electronic Cited Medium: Internet

Record details

×
Academic Journal

Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases.

  • Authors : Vande Casteele N; Department of Medicine, University of California, San Diego, La Jolla.

Subjects: Crohn Disease*/Crohn Disease*/Crohn Disease*/drug therapy ; Crohn Disease*/Crohn Disease*/Crohn Disease*/immunology ; Drug Monitoring*

  • Source: JAMA [JAMA] 2022 Apr 19; Vol. 327 (15), pp. 1506.Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases.

  • Authors : Javor E; Department of Pharmacy, General Hospital Bjelovar, Bjelovar, Croatia.; Hauser G

Subjects: Drug Monitoring* ; Gastrointestinal Agents*/Gastrointestinal Agents*/Gastrointestinal Agents*/analysis ; Gastrointestinal Agents*/Gastrointestinal Agents*/Gastrointestinal Agents*/therapeutic use

  • Source: JAMA [JAMA] 2022 Apr 19; Vol. 327 (15), pp. 1505-1506.Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases-Reply.

  • Authors : Syversen SW; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.; Jahnsen J

Subjects: Drug Monitoring* ; Gastrointestinal Agents*/Gastrointestinal Agents*/Gastrointestinal Agents*/analysis ; Gastrointestinal Agents*/Gastrointestinal Agents*/Gastrointestinal Agents*/therapeutic use

  • Source: JAMA [JAMA] 2022 Apr 19; Vol. 327 (15), pp. 1506-1507.Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Efficacy and Safety of High-dose Cholecalciferol in Patients With Inflammatory Bowel Disease Receiving Infliximab.

Subjects: Cholecalciferol*/Cholecalciferol*/Cholecalciferol*/administration & dosage ; Cholecalciferol*/Cholecalciferol*/Cholecalciferol*/adverse effects ; Inflammatory Bowel Diseases*/Inflammatory Bowel Diseases*/Inflammatory Bowel Diseases*/drug therapy

  • Source: Journal of pediatric gastroenterology and nutrition [J Pediatr Gastroenterol Nutr] 2022 Apr 01; Vol. 74 (4), pp. 476-483. Date of Electronic Publication: 2022 Jan 18.Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8211545 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

Lymphoma in Pediatric-Onset Inflammatory Bowel Disease Treated with Infliximab Monotherapy: A Case Series.

  • Authors : Llanos-Chea A; Pediatric Gastroenterology and Nutrition, Massachusetts General Hospital, CRPZ 5-560, 175 Cambridge Street, Boston, MA, 02114, USA.; Harvard Medical School, CRPZ 5-560, 175 Cambridge Street, Boston, MA, 02114, USA.

Subjects: Colitis, Ulcerative*/Colitis, Ulcerative*/Colitis, Ulcerative*/drug therapy ; Colitis, Ulcerative*/Colitis, Ulcerative*/Colitis, Ulcerative*/epidemiology ; Crohn Disease*/Crohn Disease*/Crohn Disease*/drug therapy

  • Source: Digestive diseases and sciences [Dig Dis Sci] 2022 Jan; Vol. 67 (1), pp. 252-258. Date of Electronic Publication: 2021 Feb 17.Publisher: Springer Science + Business Media Country of Publication: United States NLM ID: 7902782 Publication Model: Print-Electronic Cited Medium:

Record details

×
  • 1-10 of  184,200 results for ""INFLIXIMAB""